Positioning political selling, disclosed 2026-10-12
Options put/call open interest 1.68, read 2026-11-01
Ethical passes the values gate
Price161.57 USD
Fair value147.03
Ethical score84.7/100
RatingOVERVALUED
Our investment reviews on this name
2026-10-11Read Markup146.23+10.5% to today ✓Accumulation gives way to Markup with volume flow in agreement
2026-10-02Read Accumulation146.23+10.5% to today ✓Markdown gives way to Accumulation
2026-08-29Read Markdown142.97+13.0% to today Distribution gives way to Markdown while volume still accumulates
2026-07-02Read Distribution146.54+10.3% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Procter & Gamble holds its Markup at $161.57. Consolidating, no directional conviction, held for 6 days.
As held on the ledger · 2026-10-30
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 6 days
Price at the screen
$161.57
Valuation
24.19 trailing · 21.71 forward price to earnings
Values screen
PASS· score 84.7
Beta
0.38
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.32%
Below 33%
Interest-bearing debt is just 28.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
12.57%
Below 49%
Money owed to the company is 12.6% of assets, under the 49% limit.
Pass
Revenue purity
0.56%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Procter & Gamble clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PG's ethical verdict changes
Today PG passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic and this name passes it. Separately, community boycott lists cite this company: Cited by BDS movement for consumer products operations in Israel. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads OVERVALUED: it trades above our $147.03 fair value estimate, moderate competitive moat, 4.00% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. The price runs 9.0% above the base estimate.
Third-party analyst targets: 23 covering, consensus Buy. The average target sits +9% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $147.03, with a range of $135.90 to $169.09, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Everyday Essentials with a Premium Price Tag
Imagine your local supermarket shelves filled with familiar brands - Pampers, Gillette, Tide - all part of Procter & Gamble's everyday essentials empire. The company's broad product range and global reach have made it a household name across the globe. The numbers back up its standing; steady 2% revenue growth, an 18% profit margin, and a robust 30% return on equity, all contributing to a solid moat that's moderate but effective.
Why it stands out, however, is its current valuation. At $142.97 a share, Procter & Gamble is priced above our fair value estimate of $140.55, indicating a slight overvaluation. Despite this, the consensus among 23 analysts is a 'buy' with a median target of $162, which is a testament to the company's reputation and performance. Yet, with a forward P/E of 19.3x, there's a溢价 to pay for this consumer staple.
Risks are present, as with any investment. The moderate moat suggests that while Procter & Gamble has a competitive advantage, it isn't impenetrable. The ethical screen passes, but the overvaluation poses a risk, especially in a crowded consumer goods market where new entrants and digital disruptors can challenge traditional giants.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PG trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markup$158.26+0.8%Entry 22
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164.
2026-10-22Markup$157.08+0.0%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markup$157.08+0.0%Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markup$157.08+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markup$157.08+0.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$157.08+0.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markup$157.08+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markup$157.08+0.4%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markup$156.53+7.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-11Markup · changed$146.23+0.0%Entry 13
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (22 analysts) rates it buy, with a mean price target of $164.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
